期刊
AMERICAN JOURNAL OF THERAPEUTICS
卷 25, 期 2, 页码 E270-E272出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MJT.0000000000000517
关键词
immune-mediated thrombocytopenia purpura; bortezomib
资金
- National Institutes of Health, National Heart, Lung, and Blood Institute [T32HL007149]
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据